These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 27870570)

  • 1. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
    J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
    Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
    Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
    Xie M; Wei S; Wu X; Li X; You Y; He C
    Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
    Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
    Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
    Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
    Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
    Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
    Schwarz S; Müller M; Ettl T; Stockmann P; Zenk J; Agaimy A
    Int J Clin Exp Pathol; 2011 Apr; 4(4):336-48. PubMed ID: 21577319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
    Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
    Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
    Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
    Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma.
    Anjum S; Sen S; Pushker N; Bajaj MS; Kashyap S; Bakhshi S; Chosdol K; Meel R; Sharma MC
    Acta Ophthalmol; 2021 Dec; 99(8):e1467-e1473. PubMed ID: 33675181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening.
    Ling S; Rettig EM; Tan M; Chang X; Wang Z; Brait M; Bishop JA; Fertig EJ; Considine M; Wick MJ; Ha PK
    Int J Oncol; 2016 Jul; 49(1):225-34. PubMed ID: 27212063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
    Zhang CY; Zhao YX; Xia RH; Han J; Wang BS; Tian Z; Wang LZ; Hu YH; Li J
    PLoS One; 2014; 9(10):e110159. PubMed ID: 25302792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
    Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
    Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
    Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
    Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
    Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma.
    North JP; McCalmont TH; Fehr A; van Zante A; Stenman G; LeBoit PE
    Am J Surg Pathol; 2015 Oct; 39(10):1347-56. PubMed ID: 26076064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.